Regeneron (REGN) Tops Q2 EPS by 75c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Regeneron Pharma (REGN) PT Raised to $305 at Barclays
August 3, 2018 5:10 AM EDTBarclays raised its price target on Regeneron Pharma (NASDAQ: REGN) to $305.00 (from $290.00) while maintaining a Underweight rating.
... MoreRegeneron Pharma (REGN) PT Raised to $385 at Cowen
August 2, 2018 3:51 PM EDTCowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $385.00 (from $350.00) while maintaining a Market Perform rating.
Analyst Phil Nadeau commented, "REGN reported Q2:18 Eylea sales of $992MM, (+0.8% Q/Q, +8% Y/Y) just below the consensus $1BE. Solid performance from other key... More
Regeneron Pharma (REGN) PT Raised to $440 at Oppenheimer on Q2 Report; 'Eylea Static Decreasing, 2H18 Product Launches'
August 2, 2018 3:27 PM EDTOppenheimer raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $410.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst Hartaj Singh notes a positive outlook on the shares, as REGN reported second quarter earnings per share and sales... More
Regeneron Pharma (REGN) PT Raised to $440 at Evercore ISI
August 2, 2018 11:48 AM EDTEvercore ISI raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $405.00) while maintaining a Outperform rating.
Analyst Josh Schimer noted strong performance across the board for product revenue and expenses. Dupixent/OUS Eylea were strongest spots.
... More